Replies to post #188251 on Biotech Values

[DewDiligence]

I attended the ENTA [annual meeting] also, and did not get that impression at all.

Thanks for confirming what i suspected (i.e. no objective implication from annual-meeting presentation that ENTA management is inclined toward a buyout).

The one thing that stood out for me was their NASH initiative. Luly believes their program already to be in the forefront in the field despite its very early stage.

I interpret this to mean that the FXR target of ENTA’s preclinical drug has been “validated” by ICPT’s OCA; hence, if ENTA’s drug is somehow better than OCA, it could end up being a significant asset.